secwatch.observer — SEC 8-K summary
======================================

Issuer:     Larimar Therapeutics, Inc. (LRMR)
CIK:        0001374690
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0000950170-25-108409
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Larimar Therapeutics reports Q2 2025 net loss $26.2M; BLA for nomlabofusp on track for Q2 2026
--------------------------------------------------------------------------------

- Net loss $26.2M ($0.41/share) vs $21.6M ($0.34) in Q2 2024; R&D expenses $23.4M, up from $19.7M.
- Cash, equivalents, marketable securities $138.5M at June 30; pro forma $203.6M incl. $65.1M July offering; runway into Q4 2026.
- FDA recommends safety database: 30+ participants on 50 mg for 6 months, subset of 10 for 1 year.
- Initial 50 mg open-label and adolescent PK run-in data expected September 2025.
- Global Phase 3 sites identified in US, EU, UK, Canada, Australia; patient recruitment to begin later 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374690/000095017025108409/0000950170-25-108409-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374690/000095017025108409/lrmr-20250814.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-108409

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer